Journal
CYTOMETRY PART B-CLINICAL CYTOMETRY
Volume 90, Issue 1, Pages 21-25Publisher
WILEY
DOI: 10.1002/cyto.b.21272
Keywords
plasma cell myeloma; minimal residual disease; PCR; flow cytometry; high throughput sequencing; quantification; rare event detection
Categories
Funding
- Intramural NIH HHS [Z01 BC011104] Funding Source: Medline
Ask authors/readers for more resources
Treatment options for myeloma continue to develop at a rapid pace, and it is becoming increasingly challenging to determine the optimal therapeutic approaches because demonstrating a clear survival benefit now requires many years of follow-up. The detection of minimal residual disease (MRD) is recognized as a sensitive and rapid approach to evaluate treatment efficacy that predicts progression-free and overall survival independent of categorical response assessment and patients' biology. The benefit of MRD analysis is reflected in the many different techniques (multiparameter flow cytometry, quantitative polymerase chain reaction, and high-throughput sequencing) and collaborative groups (including EMN, ESCCA, ICCS, Euro-Flow, and EuroMRD) that have performed collaborative projects to harmonize quantitative MRD detection. The time has come to adopt a consensus approach, and this report reviews the benefits and disadvantages of different strategies for MRD detection in myeloma and highlights the requirements for a sensitive, reproducible, and clinically meaningful cellular analytical approach. (C) 2015 International Clinical Cytometry Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available